Bionity.COM Newsletter No. 50/2009, 12/16/2009

New Products and Services

> more

Detect Glucan Contamination in Under 30 Minutes
Charles River Unveils New PTS^TM Application for Detection of Glucans
The Endosafe^®-PTS^TM Glucan Assay is a rapid test designed for investigational purposes to validate that your products are free of (1,3)-ß-D glucans, which are molecules that are found in the cell walls of most yeasts and molds. Glucans contaminate cell culture fluid, yeast protein production, air quality samples, and cellulose filter preparations...

http://www.bionity.com/products/e/107447/

Request information

New Synergy^TM 4 Microplate Reader combines both filter-based and quadruple monochromator-based fluorescence detection technology
BioTek's new Synergy^TM4 with Hybrid Technology combines two powerful detection systems, filter-based and monochromator-based, in one unit. As a result, you can finally enjoy complete flexibiltiy and instant control in assay choice for current as well as future demands...

http://www.bionity.com/products/e/66199/

Request information

Unique Raman-AFM Microscope Combination for Automated 3-D Chemical Imaging and Surface Inspection
WITec introduces the alpha500 and alpha700 series for automated Confocal Raman Imaging and Atomic Force Microscopy
The new alpha500 and alpha700 series allows for the automated chemical and structural characterization of large samples for the most comprehensive and rapid surface inspection on the sub-micron scale...

http://www.bionity.com/products/e/76485/

Request information

Biotech News

> more

Latest News from Biotechnology and Pharma from 12/09/2009 to 12/15/2009

Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops
12/15/2009 - Biologists have identified plant enzymes that may help to engineer plants that take advantage of elevated carbon dioxide to use water more efficiently. The finding could help to engineer crops that ta...
http://www.bionity.com/news/e/110828/

Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis
12/15/2009 - Welichem announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, ...
http://www.bionity.com/news/e/110818/

Sanofi-aventis doubles syringe production capacity and diversifies vaccine production at the Le Trait Manufacturing Plant
12/15/2009 - Sanofi-aventis launched its new production units at the Le Trait site in a ceremony attended by Jean-Marie Aline, Mayor of Le Trait, Christophe Bouillon, Member of the French National Assembly for Sei...
http://www.bionity.com/news/e/110816/

Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development
12/15/2009 - Oncolytics Biotech Inc. announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development.
In his 32-year career, Dr. Warrander has he...
http://www.bionity.com/news/e/110817/

Scientists use nanosensors for first time to measure cancer biomarkers in blood
12/15/2009 - A team led by Yale University researchers has used nanosensors to measure cancer biomarkers in whole blood for the first time. Their findings, which appear in Nature Nanotechnology , could dramaticall...
http://www.bionity.com/news/e/110829/

Successful Stem Cell Therapy for Treatment of Eye Disease
12/14/2009 - Newly published research, by investigators, at the North East England Stem Cell Institute (NESCI) in the journal Stem Cells reported the first successful treatment of eight patients with "Limbal Stem ...
http://www.bionity.com/news/e/110761/

IASB Welcomes New Recommendations of the U.S. Government for Biosecurity in Synthetic Gene Production
12/14/2009 - Recently the U.S. Government published recommendations for the production of synthetic genes. Those recommendations have been requested by associations like the International Association Synthetic Bio...
http://www.bionity.com/news/e/110812/

New Phase II study showed trastuzumab-DM1 shrank tumours in women with highly advanced HER2-positive breast cancer
T-DM1, an Investigational Antibody-Drug Conjugate, Showed Encouraging Results in Women Who Have Received Multiple Prior Medicines
12/14/2009 - Roche announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of wome...
http://www.bionity.com/news/e/110814/

YM Biosciences and NRC Biotechnology Research Institute Produce New Breast Cancer Drug Candidates
12/14/2009 - YM BioSciences Inc. announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliM...
http://www.bionity.com/news/e/110775/

Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board
12/14/2009 - GVK Biosciences (GVK BIO) announced the appointment of Dr. Cecil B. Pickett as Scientific Advisor to the Board of Directors.
Cecil B. Pickett, Ph.D. has served as President of Research and Develop...
http://www.bionity.com/news/e/110809/

Effort to regenerate damaged spinal cords turns to new model
12/11/2009 - For more than 400 years, scientists have studied the amazing regenerative power of salamanders, trying to understand how these creatures routinely repair injuries that would usually leave humans and o...
http://www.bionity.com/news/e/110752/

Drug Candidates in Pipeline Offer Potential for Parkinson’s Disease Therapeutics Market, Says Frost & Sullivan
12/11/2009 - The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT ...
http://www.bionity.com/news/e/110689/

Breakthrough positive phase III results with acyclovir Lauriad: Primary and secondary endpoints met
12/11/2009 - BioAlliance Pharma SA announced final positive results of its pivotal phase III clinical study in immunocompetent patients with recurrent herpes labialis (LIP Study) treated with acyclovir Lauriad®. ...
http://www.bionity.com/news/e/110758/

Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines
12/11/2009 - Intercell and GlaxoSmithKline Biologicals SA (GSK) announced an agreement to form a strategic alliance to accelerate the development and commercialization of needle-free, patch-based vaccines. The agr...
http://www.bionity.com/news/e/110751/

Sirius Genomics Announces Change in Leadership
12/11/2009 - Sirius Genomics announced that Chris Wagner has been appointed President and Chief Executive Officer, replacing Dr.Brad Popovich. Dr. Popovich will continue as member of Sirius Genomics Board and will...
http://www.bionity.com/news/e/110702/

BD Biosciences Announces First Winners of Expanded Research Grant Program
12/10/2009 - BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced the first seven winners of its expanded BD Biosciences Research Grant Program who will receive research reagents valued at a ...
http://www.bionity.com/news/e/110663/

Cell Biosciences Acquires Protein Forest
12/10/2009 - Cell Biosciences, Inc. announced that it has acquired Protein Forest, Inc. This strategic acquisition adds Protein Forest's digital ProteomeChip(TM) product line to Cell Biosciences' portfolio of prod...
http://www.bionity.com/news/e/110575/

Genzyme’s Mozobil Shows Promise in Chemosensitization
12/10/2009 - Genzyme Corporation announced that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leu...
http://www.bionity.com/news/e/110658/

Generex inks deal with Sanofi-Aventis for insulin supply
12/10/2009 - Generex Biotechnology Corporation announced that it has signed a long-term agreement with Sanofi-Aventis Deutschland GmbH for the manufacture and supply of recombinant human insulin crystals for com...
http://www.bionity.com/news/e/110686/

Robert J. Bertolini Elected to Genzyme’s Board of Directors
12/10/2009 - Genzyme Corporation announced the election of Robert J. Bertolini to the company’s board of directors. Mr. Bertolini was executive vice president and chief financial officer at Schering-Plough Corp. u...
http://www.bionity.com/news/e/110651/

Delivering medicine directly into a tumor
Peptide delivers anti-cancer compounds to where they can do the most good
12/09/2009 - Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide that specifically recognizes and penetrates cancerous tumors but not normal t...
http://www.bionity.com/news/e/110569/

Mérieux Alliance Becomes Institut Mérieux
Alain Mérieux Confirms the Institute';s Commitment to Meeting new Medical and Public Health Challenges
12/09/2009 - Mérieux Alliance, the Mérieux family holding company, announced that it changes its name to take on the historic name of Institut Mérieux. At a press conference held in Paris, Alain Mérieux reviewed t...
http://www.bionity.com/news/e/110574/

Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
12/09/2009 - Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) (FluCAM) to Fludara alone in ...
http://www.bionity.com/news/e/110558/

New technology could boost disease detection tests' speed and sensitivity
12/09/2009 - A team led by Yale University scientists has developed a way to rapidly manipulate and sort different cells in the blood using magnetizable liquids. The findings, published in the Proceedings of the N...
http://www.bionity.com/news/e/110570/

Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia
12/09/2009 - Santhera Pharmaceuticals presented the potential of its oral melanocortin-4 receptor (MC-4R) antagonists for treatment of cancer cachexia at the 5th Cachexia conference in Barcelona, Spain. The Compa...
http://www.bionity.com/news/e/110556/

Catalogues and Brochures

> more

Expression Studies at all Levels? Find new Approaches in: SABiosciences Pathways No. 8
Meet the new PCR based Epigenetics Kits
The long time number one method in cellular signaling research, Real Time PCR, and the hot topic, Epigenetics: find out how to use one to advance the other: SABiosciences Pathways No. 8...

http://www.bionity.com/catalogs/e/95068/

Order catalogue

Events

> more

Events, Workshops and Training Courses